• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, Aug. 8

Zenotech Laboratories Ltd (ZLL) has announced that it has received marketing and manufacturing approval for two of its biotech products — GM-CSF (Innovator brand: Leucomax by Novartis) and G-CSF (Neupogen by Amgen/Roche). In a press release here on Tuesday, the company said both the products are used by the oncology specialists to treat neutropenia in cancer patients. The company said it would be launching both the products in India in the next few days. Zenotech said it is the first Indian company to develop generic version of GM-CSF.

According to the release, Zenotech's biologics manufacturing facility was inspected by the Drug Controller General of India (DCGI) and by scientists from National Institute of Biologicals. The biologics facility is about 1-lakh square feet and meets US FDA and EU specifications. Further, the company said it is currently in discussions with potential partners to take its G-CSF to the European Union.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Actuaries to get guidance on valuation of staff benefits soon

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line